Hyqvia is a combination of Immune Globulin Infusion 10% (Human) (IG 10%) and Recombinant Human Hyaluronidase developed by Halozyme. The first subcutaneous immune globulin (IG) treatment is approved
The approval allows the tablets for use in chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27
CLT-008 is a first-in-class, allogeneic, cell-based therapy to treat hematopoietic sub-syndrome of Acute Radiation Syndrome (ARS). The recent funding is in addition to the $116.4m committed under the
The Phase IIb trial was assessing the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury (STOP-TBI). The decision to halt the trial comes
The company intends to submit an investigational new drug (IND) application for VT-1129 to the FDA in the first half of 2015. In preclinical trials, VT-1129 has been
The Phase III PIONEER I trial showed that Humira is effective in reducing common clinical signs and symptoms in moderate-to-severe HS, specifically the number of abscesses and inflammatory
The trial will assess the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults. About 90
As part of the deal, Asterias will complete development of the manufacturing process for AST-VAC2, after which CRT will produce the vaccine and conduct the Phase I/II clinical
The approval for the use of new indication follows a priority review of the supplemental new drug application (sNDA) that was based on results of the Phase III
Regenacyn is formulated from the company’s Microcyn Technology platform and is designed to address the underserved consumer scar management market. The company said that the hydrogel has been
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.